Journal
JACC-BASIC TO TRANSLATIONAL SCIENCE
Volume 3, Issue 4, Pages 450-463Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacbts.2018.03.006
Keywords
arginase; nitric oxide synthase; reactive oxygen species; red blood cells; type 2 diabetes
Categories
Funding
- Swedish Research Council [2016-01284, 2013-66-104153-33]
- Swedish Heart and Lung Foundation [20160239]
- Stockholm County Council [20160084]
- Karolinska Institutet/Stockholm County Council Strategic Cardiovascular Programme [20120741]
- Soderberg Foundation [M60/15]
- Family Erling-Persson Foundation
- Diabetes Research and Wellness Foundation [720-1519-16]
- EU-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action [CA16225]
- Vinnova [2016-01284] Funding Source: Vinnova
Ask authors/readers for more resources
This study tested the hypothesis that red blood cell (RBC) arginase represents a potential therapeutic target in ischemia-reperfusion in type 2 diabetes. Post-ischemic cardiac recovery was impaired in hearts from db/db mice compared with wild-type hearts. RBCs from mice and patients with type 2 diabetes attenuated post-ischemic cardiac recovery of nondiabetic hearts. This impaired cardiac recovery was reversed by inhibition of RBCs arginase or nitric oxide synthase. The results suggest that RBCs from type 2 diabetics impair cardiac tolerance to ischemia-reperfusion via a pathway involving arginase activity and nitric oxide synthase-dependent oxidative stress. (C) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available